Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy - Tabular View

Tracking Information
First Received Date ^ICMJE	May 24, 2004
Last Updated Date	June 29, 2007
Start Date ^ICMJE
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00083434 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
Official Title ^ICMJE
Brief Summary	The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.
Detailed Description
Study Phase	Phase III
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Efficacy Study
Condition ^ICMJE	Anemia Cancer
Intervention ^ICMJE	Drug: Epoetin alfa
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Terminated
Enrollment ^ICMJE
Completion Date	December 2004
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion Criteria: 18 years of age or older Body weight >/= 99lbs ECOG 0-2 Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy Screening hemoglobin level of </= 11.0 g/dL for men or </= 10.0 for women Exclusion Criteria: History of or concurrent second malignancy Evidence of primary or metastatic malignancy involving the Central Nervous System
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT ID ^ICMJE	NCT00083434
Responsible Party
Study ID Numbers ^ICMJE	EPO-CAN-303
Study Sponsor ^ICMJE	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Verification Date	June 2007
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP